|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/23/22 Sigyn Therapeutics, Inc. S-1 63:7.7M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: S-1 Registration Statement (General Form) HTML 1.75M
2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 94K
3: EX-23.1 Consent of Expert or Counsel HTML 18K
4: EX-FILING FEES Filing Fees HTML 23K
10: R1 Cover HTML 52K
11: R2 Condensed Consolidated Balance Sheets HTML 120K
12: R3 Condensed Consolidated Balance Sheets HTML 29K
(Parenthetical)
13: R4 Condensed Consolidated Statements of Operations HTML 90K
14: R5 Condensed Consolidated Statements of Stockholders' HTML 76K
Deficit
15: R6 Condensed Consolidated Statements of Cash Flows HTML 112K
16: R7 Organization and Principal Activities HTML 49K
17: R8 Basis of Presentation HTML 34K
18: R9 Summary of Significant Accounting Policies HTML 117K
19: R10 Property and Equipment HTML 46K
20: R11 Intangible Assets HTML 49K
21: R12 Convertible Promissory Debentures HTML 342K
22: R13 Stockholders? Deficit HTML 74K
23: R14 Operating Leases HTML 82K
24: R15 Related Party Transactions HTML 40K
25: R16 Income Taxes HTML 50K
26: R17 Earnings Per Share HTML 51K
27: R18 Commitments and Contingencies HTML 24K
28: R19 Subsequent Events HTML 36K
29: R20 Summary of Significant Accounting Policies HTML 159K
(Policies)
30: R21 Property and Equipment (Tables) HTML 42K
31: R22 Intangible Assets (Tables) HTML 47K
32: R23 Convertible Promissory Debentures (Tables) HTML 73K
33: R24 Operating Leases (Tables) HTML 73K
34: R25 Income Taxes (Tables) HTML 47K
35: R26 Earnings Per Share (Tables) HTML 45K
36: R27 Organization and Principal Activities (Details HTML 44K
Narrative)
37: R28 Basis of Presentation (Details Narrative) HTML 39K
38: R29 Summary of Significant Accounting Policies HTML 42K
(Details Narrative)
39: R30 Schedule of Property and Equipment (Details) HTML 34K
40: R31 Property and Equipment (Details Narrative) HTML 21K
41: R32 Schedule of Intangible Assets (Details) HTML 33K
42: R33 Schedule of Estimated Future Amortization Expense HTML 25K
Related to Intangible Assets (Details)
43: R34 Intangible Assets (Details Narrative) HTML 21K
44: R35 Schedule of Convertible Notes Payable (Details) HTML 40K
45: R36 Schedule of Convertible Notes Payable (Details) HTML 62K
(Parenthetical)
46: R37 Convertible Promissory Debentures (Details HTML 370K
Narrative)
47: R38 Stockholders? Deficit (Details Narrative) HTML 115K
48: R39 Schedule of Operating Lease Cost and Supplemental HTML 35K
Cash Flow Information (Details)
49: R40 Schedule of Maturities of Operating Lease HTML 50K
Liabilities (Details)
50: R41 Operating Leases (Details Narrative) HTML 30K
51: R42 Related Party Transactions (Details Narrative) HTML 55K
52: R43 Schedule of Reconciliation of Statutory Income Tax HTML 31K
Rates and Effective Tax Rate (Details)
53: R44 Schedule of Deferred Tax Assets (Details) HTML 24K
54: R45 Income Taxes (Details Narrative) HTML 22K
55: R46 Schedule of Computation of Basic and Diluted Net HTML 45K
Income Per Share (Details)
56: R47 Schedule of Estimated Amortization Expenses HTML 25K
Related to Intangible Assets (Details)
57: R48 Schedule of Principal Payments Due on Convertible HTML 27K
Promissory Debentures (Details)
58: R49 Subsequent Events (Details Narrative) HTML 44K
61: XML IDEA XML File -- Filing Summary XML 111K
59: XML XBRL Instance -- forms-1_htm XML 1.82M
60: EXCEL IDEA Workbook of Financial Reports XLSX 109K
6: EX-101.CAL Inline XBRL Taxonomy Extension Calculation XML 146K
Linkbase Document -- sign-20220331_cal
7: EX-101.DEF Inline XBRL Taxonomy Extension Definition Linkbase XML 403K
Document -- sign-20220331_def
8: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 784K
Document -- sign-20220331_lab
9: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 611K
Linkbase Document -- sign-20220331_pre
5: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 115K
sign-20220331
62: JSON XBRL Instance as JSON Data -- MetaLinks 281± 380K
63: ZIP XBRL Zipped Folder -- 0001493152-22-017538-xbrl Zip 320K
Exhibit 107
CALCULATION OF REGISTRATION FEE
| Title of Each Class of Securities to Be Registered | Proposed Maximum Offering Price (1) | Amount of Registration Fee (2) | ||||||
| Units consisting of: | ||||||||
| (i) Shares of common stock, par value $0.001 per share (2)(3)(4) | $ | 9,200,000 | $ | 852.84 | ||||
| (ii) Series A Warrants to purchase shares of common stock, par value $0.001 per share (3)(4)(5) | - | - | ||||||
| Series B Preferred Stock (8) | ||||||||
| Common Stock issuable upon conversion of Series B Preferred Stock | ||||||||
| Shares of common stock, par value $0.001 per share underlying Series A Warrants (2) | $ | 10,120,000 | $ | 938.12 | ||||
| Underwriters’ common stock purchase warrants (6) | - | - | ||||||
| Common stock underlying underwriters’ common stock purchase warrants (2)(7) | $ | 667,920 | $ | 61.92 | ||||
| Total | $ | 19,987,920 | $ | 1,852.88 | ||||
| (1) | Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. |
| (2) | Pursuant to Rule 416, there are also being registered such indeterminable additional securities as may be issued to prevent dilution as a result of stock splits, stock dividends or similar transactions. |
| (3) | Includes shares the underwriter has the option to purchase to cover over-allotments, if any. |
| (4) | In accordance with Rule 457(i) under the Securities Act, no separate registration fee is required with respect to the warrants registered hereby. |
| (5) | There will be issued warrants to purchase one share of common stock. The Series A Warrants are exercisable at a per share exercise price equal to 110% of the public offering price of one Class A Unit. We estimate that the maximum offering price for each Class A A Unit is $___ to $___, and the maximum number of shares shall be ____ to ____, assuming no exercise of the overallotment. |
| (6) | No fee pursuant to Rule 457(g) under the Securities Act. |
| (7) | The warrants are exercisable at a per share exercise price equal to 110% of the public offering price of the Class A Units. As estimated solely for the purpose of recalculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the underwriters’ warrants is equal to 110% of $607,200 (6% of $10,120,000). |
| (8) | No separate fee required pursuant to Rule 457 under the Securities Act of 1933. |
C:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/10/24 Sigyn Therapeutics, Inc. S-1/A 68:29M M2 Compliance LLC/FA 9/22/23 Sigyn Therapeutics, Inc. S-1/A 66:13M M2 Compliance LLC/FA 5/10/23 Sigyn Therapeutics, Inc. S-1/A 64:8.6M M2 Compliance LLC/FA 2/28/23 Sigyn Therapeutics, Inc. S-1/A 26:7.5M M2 Compliance LLC/FA 12/23/22 Sigyn Therapeutics, Inc. S-1/A 67:36M M2 Compliance LLC/FA 11/07/22 Sigyn Therapeutics, Inc. S-1/A 74:208M M2 Compliance LLC/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/02/16 Sigyn Therapeutics, Inc. 8-K:1,2,3,912/01/16 6:531K S2 Filings LLC/FA 11/14/16 Sigyn Therapeutics, Inc. 8-K:1,2,3,511/10/16 5:728K S2 Filings LLC/FA 12/24/15 Sigyn Therapeutics, Inc. 8-K:1,3,5,812/22/15 10:1.2M S2 Filings LLC/FA 5/27/15 Sigyn Therapeutics, Inc. S-1 10:3.4M S2 Filings LLC/FA |